BRPI0910832B8 - derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. - Google Patents

derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.

Info

Publication number
BRPI0910832B8
BRPI0910832B8 BRPI0910832A BRPI0910832A BRPI0910832B8 BR PI0910832 B8 BRPI0910832 B8 BR PI0910832B8 BR PI0910832 A BRPI0910832 A BR PI0910832A BR PI0910832 A BRPI0910832 A BR PI0910832A BR PI0910832 B8 BRPI0910832 B8 BR PI0910832B8
Authority
BR
Brazil
Prior art keywords
ampk
activators
intermediates
protein kinase
activated protein
Prior art date
Application number
BRPI0910832A
Other languages
English (en)
Portuguese (pt)
Inventor
Charon Christine
Cravo Daniel
Lepifre Franck
Hallakou-Bozec Sophie
Original Assignee
Merck Patent Ges Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910832(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Ges Mit Beschraenkter Haftung filed Critical Merck Patent Ges Mit Beschraenkter Haftung
Publication of BRPI0910832A2 publication Critical patent/BRPI0910832A2/pt
Publication of BRPI0910832A8 publication Critical patent/BRPI0910832A8/pt
Publication of BRPI0910832B1 publication Critical patent/BRPI0910832B1/pt
Publication of BRPI0910832B8 publication Critical patent/BRPI0910832B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0910832A 2008-05-05 2009-04-08 derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. BRPI0910832B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290423.6 2008-05-05
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (4)

Publication Number Publication Date
BRPI0910832A2 BRPI0910832A2 (pt) 2015-08-11
BRPI0910832A8 BRPI0910832A8 (pt) 2016-07-12
BRPI0910832B1 BRPI0910832B1 (pt) 2020-09-15
BRPI0910832B8 true BRPI0910832B8 (pt) 2021-05-25

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910832A BRPI0910832B8 (pt) 2008-05-05 2009-04-08 derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.

Country Status (26)

Country Link
US (1) US8604202B2 (enExample)
EP (1) EP2280952B1 (enExample)
JP (1) JP5536757B2 (enExample)
KR (2) KR101648593B1 (enExample)
CN (1) CN102015676B (enExample)
AR (1) AR071530A1 (enExample)
AU (1) AU2009243811B2 (enExample)
BR (1) BRPI0910832B8 (enExample)
CA (1) CA2723429C (enExample)
CO (1) CO6331304A2 (enExample)
CY (1) CY1113112T1 (enExample)
DK (1) DK2280952T3 (enExample)
EA (1) EA020773B1 (enExample)
EC (1) ECSP10010654A (enExample)
ES (1) ES2388485T3 (enExample)
HR (1) HRP20120549T1 (enExample)
IL (1) IL208988A (enExample)
MX (1) MX2010011916A (enExample)
MY (1) MY160357A (enExample)
NZ (1) NZ589690A (enExample)
PL (1) PL2280952T3 (enExample)
PT (1) PT2280952E (enExample)
SI (1) SI2280952T1 (enExample)
UA (1) UA103617C2 (enExample)
WO (1) WO2009135580A1 (enExample)
ZA (1) ZA201008722B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
KR101624020B1 (ko) * 2011-03-07 2016-05-24 글락소스미스클라인 엘엘씨 퀴놀리논 유도체
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
EP3310355B1 (en) 2015-06-16 2020-11-11 University of Virginia Patent Foundation Ptp4a3 inhibitor for the treatment of cancer
PL3322711T3 (pl) 2015-06-25 2021-10-25 University Health Network Inhibitory hpk1 i sposoby ich zastosowania
EP3355876A2 (en) 2015-09-30 2018-08-08 Instituto de Medicina Molecular Methods for attenuating parasite virulence
US11584755B2 (en) 2017-09-26 2023-02-21 Ideaya Biosciences, Inc. Dihydrothieno[3,2-b]pyridine compounds
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
US12404348B2 (en) 2021-11-19 2025-09-02 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) * 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
US20090149495A1 (en) * 2005-12-20 2009-06-11 Katalin Nogradi Compounds
MX2010011047A (es) * 2008-04-11 2010-10-26 Merck Patent Gmbh Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk).

Also Published As

Publication number Publication date
IL208988A (en) 2016-02-29
CN102015676A (zh) 2011-04-13
KR20160038065A (ko) 2016-04-06
CN102015676B (zh) 2014-05-28
KR101648593B1 (ko) 2016-08-16
CO6331304A2 (es) 2011-10-20
AU2009243811A1 (en) 2009-11-12
NZ589690A (en) 2012-07-27
CY1113112T1 (el) 2016-04-13
EP2280952B1 (en) 2012-06-27
US20110060001A1 (en) 2011-03-10
CA2723429A1 (en) 2009-11-12
ECSP10010654A (es) 2011-01-31
CA2723429C (en) 2016-10-11
PL2280952T3 (pl) 2012-10-31
AU2009243811B2 (en) 2014-04-10
BRPI0910832A8 (pt) 2016-07-12
IL208988A0 (en) 2011-01-31
EP2280952A1 (en) 2011-02-09
MX2010011916A (es) 2010-11-26
EA201001733A1 (ru) 2011-06-30
ES2388485T3 (es) 2012-10-15
WO2009135580A1 (en) 2009-11-12
SI2280952T1 (sl) 2012-09-28
JP2011519876A (ja) 2011-07-14
MY160357A (en) 2017-02-28
JP5536757B2 (ja) 2014-07-02
EA020773B1 (ru) 2015-01-30
PT2280952E (pt) 2012-09-28
ZA201008722B (en) 2012-01-25
BRPI0910832B1 (pt) 2020-09-15
DK2280952T3 (da) 2012-07-23
BRPI0910832A2 (pt) 2015-08-11
UA103617C2 (ru) 2013-11-11
HK1156313A1 (en) 2012-06-08
HRP20120549T1 (hr) 2012-07-31
US8604202B2 (en) 2013-12-10
KR20110010757A (ko) 2011-02-07
AR071530A1 (es) 2010-06-23

Similar Documents

Publication Publication Date Title
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112013019124A2 (pt) grupo substituinte de fósforo contendo quinolina como composto, seu processo de preparação, composição médica contendo o composto e aplicação
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BRPI0709680B8 (pt) derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BRPI0718813B8 (pt) compostos derivados de 1,1-dióxido de 1,4-benzotiepina, medicamento que os compreendem e seus usos
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112013020605A2 (pt) derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.